Paula Cohen, associate vice provost for life sciences, is leading an eight-year, $8 million, multi-institution grant to untangle the complex genetic rulebook for how sperm develops.
A Baker Institute for Animal Health study finds the antimicrobial properties of certain stem cell proteins could help treat skin infections that are resistant to antibiotics.
A $5.1 million research project just launched at Cornell University, the University of Washington, and the University of Arizona that may offer some hope by investigating the potential links between Alzheimer’s disease and a similar condition in dogs called canine cognitive dysfunction.
Embark Veterinary, Inc. – a canine genetics startup company that graduated from Cornell’s McGovern Center incubator in late 2017 – announced $75 million in venture funding on July 26.
Over a million hours of sound recordings are available from the Elephant Listening Project (ELP) in the K. Lisa Yang Center for Conservation Bioacoustics at the Cornell Lab of Ornithology – a rainforest residing in the cloud.
The Samuel Curtis Johnson Graduate School of Management is announcing a new BioEntrepreneurship Initiative to connect MBA students and life science researchers to life science companies in NYS while catalyzing the formation of new life science startups.
Teddy was diagnosed with the most common type of cancer for dogs: Lymphoma, a blood cancer that starts in the lymph nodes and can infiltrate any organ in the body, including the eyes.
FARVets, a nonprofit run through the College of Veterinary Medicine to address animal overpopulation with spay-neuter clinics and vaccinations, has extended its reach in New York state as it has had to limit international programming because of the COVID-19 pandemic.
By testing easier-to-study coyotes, researchers from the Cornell Wildlife Health Lab at the College of Veterinary Medicine, in collaboration with the Cheyenne River Sioux tribe, have identified a range of lethal diseases threatening black-footed ferrets – one of the most endangered animals in North America.
Elucida Oncology, a biotechnology company based on C Dots – ultra-small nanoparticles developed at Cornell that show promise in identifying and fighting cancer – recently secured $44 million in financing.